KR20230044404A - 코로나바이러스에 대한 면역 반응을 유도하기 위한 조성물 및 방법 - Google Patents

코로나바이러스에 대한 면역 반응을 유도하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230044404A
KR20230044404A KR1020237002322A KR20237002322A KR20230044404A KR 20230044404 A KR20230044404 A KR 20230044404A KR 1020237002322 A KR1020237002322 A KR 1020237002322A KR 20237002322 A KR20237002322 A KR 20237002322A KR 20230044404 A KR20230044404 A KR 20230044404A
Authority
KR
South Korea
Prior art keywords
coronavirus
cpg
antigen
peptide
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237002322A
Other languages
English (en)
Korean (ko)
Inventor
마틴 피. 스틴벅
로차나 엠. 시나파
피터 씨. 데무스
크리스토퍼 엠. 하크
리사 맥네일
Original Assignee
엘리시오 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘리시오 테라퓨틱스, 인크. filed Critical 엘리시오 테라퓨틱스, 인크.
Publication of KR20230044404A publication Critical patent/KR20230044404A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237002322A 2020-06-26 2021-06-25 코로나바이러스에 대한 면역 반응을 유도하기 위한 조성물 및 방법 Pending KR20230044404A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063044773P 2020-06-26 2020-06-26
US63/044,773 2020-06-26
US202063064836P 2020-08-12 2020-08-12
US63/064,836 2020-08-12
US202063124200P 2020-12-11 2020-12-11
US63/124,200 2020-12-11
US202163145200P 2021-02-03 2021-02-03
US63/145,200 2021-02-03
PCT/US2021/039134 WO2021263131A1 (en) 2020-06-26 2021-06-25 Compositions and methods for inducing an immune response against coronavirus

Publications (1)

Publication Number Publication Date
KR20230044404A true KR20230044404A (ko) 2023-04-04

Family

ID=79281915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002322A Pending KR20230044404A (ko) 2020-06-26 2021-06-25 코로나바이러스에 대한 면역 반응을 유도하기 위한 조성물 및 방법

Country Status (9)

Country Link
US (1) US20230263882A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171574A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532290A (cg-RX-API-DMAC7.html)
KR (1) KR20230044404A (cg-RX-API-DMAC7.html)
AU (1) AU2021294342A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026580A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183735A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000041A (cg-RX-API-DMAC7.html)
WO (1) WO2021263131A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
WO2022043551A2 (en) * 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
WO2023114570A1 (en) * 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023159081A2 (en) * 2022-02-15 2023-08-24 Ohio State Innovation Foundation Nanotechnology based intranasal vaccine for covid-19
CN114752631B (zh) * 2022-06-15 2022-09-02 中国人民解放军军事科学院军事医学研究院 Rna及包含其的新型冠状病毒疫苗和制备方法
JP2026519945A (ja) * 2023-04-26 2026-06-19 エリシオ セラピューティクス, インク. ポリヌクレオチド及びポリペプチド両親媒性物質を含有する組成物並びにその使用方法
WO2025240477A1 (en) * 2024-05-17 2025-11-20 The Regents Of The University Of California Methods and materials for enhancing delivery of nucleic acid to cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108937A1 (en) * 2003-06-04 2004-12-16 Bioleaders Corporation Cell surface expression vector of sars virus antigen and microorganisms transformed thereby
WO2006009011A1 (ja) * 2004-07-15 2006-01-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute コロナウイルススパイクs1融合蛋白及びその発現ベクター
JP6375289B2 (ja) * 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
EP3075393A4 (en) * 2013-11-29 2017-08-16 Terumo Kabushiki Kaisha Adjuvant composition, vaccine composition comprising same, and method for producing same
US12247052B2 (en) * 2018-03-02 2025-03-11 Elicio Therapeutics, Inc. CpG amphiphiles and uses thereof
BR112022015565A2 (pt) * 2020-02-07 2022-09-27 Modernatx Inc Vacinas de domínio de mrna para sars-cov-2

Also Published As

Publication number Publication date
WO2021263131A1 (en) 2021-12-30
BR112022026580A2 (pt) 2023-01-24
EP4171574A4 (en) 2024-10-23
MX2023000041A (es) 2023-03-10
CA3183735A1 (en) 2021-12-30
US20230263882A1 (en) 2023-08-24
AU2021294342A1 (en) 2023-02-23
JP2023532290A (ja) 2023-07-27
EP4171574A1 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
US20230263882A1 (en) Compositions and methods for inducing an immune response against coronavirus
US20230277652A1 (en) Nucleic acid vaccines for coronavirus
ES2992653T3 (en) Methods of preparing lipid nanoparticles
US20210317169A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
CN110381994B (zh) 用于诱导针对寨卡病毒的免疫应答的核苷修饰的rna
JP4535211B2 (ja) コクリエート送達ビヒクル
US8557247B2 (en) Lyophilised antigen composition
EP3852728A1 (en) Preparation of lipid nanoparticles and methods of administration thereof
US20030072768A1 (en) Method to enhance an immune response of nucleic acid vaccination
IL293571B2 (en) Coronavirus vaccine
JP2026082987A (ja) クロストリディオイデス(クロストリジウム)・ディフィシル(clostridioides(clostridium)difficile)に対する免疫応答を誘発するための免疫原性組成物および方法
TW202502375A (zh) 用於治療披衣菌之組合物
Zeng et al. Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity
CN117083291B (zh) 基于源自SARS-CoV-2 Delta毒株的序列的冠状病毒核酸疫苗
US20220370591A1 (en) Compositions comprising nucleic acids encoding structural trimers and methods of using the same
CN121285384A (zh) 用于在痤疮的治疗中使用的组合物
JP2025529906A (ja) コロナウイルスに対するワクチン
CN116507344A (zh) 用于诱导针对冠状病毒的免疫应答的组合物和方法
HK40097857A (en) Compositions and methods for inducing an immune response against coronavirus
TW202517779A (zh) 牙齦卟啉單胞菌抗原性構築體
HK40016066B (en) Nucleoside-modified rna for inducing an immune response against zika virus
AU2013213688A1 (en) Lyophilised antigen composition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902